Catalyst Pharmaceuticals Number Of Shares Shorted vs. Revenue

CPRX Stock  USD 22.07  0.27  1.21%   
Based on Catalyst Pharmaceuticals' profitability indicators, Catalyst Pharmaceuticals is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in December. Profitability indicators assess Catalyst Pharmaceuticals' ability to earn profits and add value for shareholders. Operating Cash Flow Sales Ratio is likely to rise to 0.38 in 2024, whereas Price To Sales Ratio is likely to drop 4.26 in 2024. At this time, Catalyst Pharmaceuticals' Change To Netincome is fairly stable compared to the past year. Net Income Per Share is likely to rise to 0.71 in 2024, whereas Net Interest Income is likely to drop slightly above 1 M in 2024.
For Catalyst Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Catalyst Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Catalyst Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Catalyst Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Catalyst Pharmaceuticals over time as well as its relative position and ranking within its peers.
  

Catalyst Pharmaceuticals' Revenue Breakdown by Earning Segment

Check out Trending Equities.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.18
Revenue Per Share
3.999
Quarterly Revenue Growth
0.253
Return On Assets
0.1835
Return On Equity
0.2829
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Catalyst Pharmaceuticals Revenue vs. Number Of Shares Shorted Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Catalyst Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Catalyst Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Catalyst Pharmaceuticals is number one stock in number of shares shorted category among its peers. It also is the top company in revenue category among its peers totaling about  70.11  of Revenue per Number Of Shares Shorted. At this time, Catalyst Pharmaceuticals' Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Catalyst Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Catalyst Revenue vs. Number Of Shares Shorted

Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Catalyst Pharmaceuticals

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
5.68 M
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Catalyst Pharmaceuticals

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
398.2 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Catalyst Revenue vs Competition

Catalyst Pharmaceuticals is the top company in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 412.53 Million. Catalyst Pharmaceuticals totals roughly 398.2 Million in revenue claiming about 97% of equities under Health Care industry.

Catalyst Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Catalyst Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Catalyst Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Catalyst Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Catalyst Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income14 K14.7 K
Operating Income86.8 M91.2 M
Income Before Tax94.5 M99.2 M
Net Income71.4 M75 M
Income Tax Expense23.1 M24.3 M
Total Other Income Expense Net7.7 M8.1 M
Net Income From Continuing Ops62 M65.1 M
Non Operating Income Net Other3.3 M3.5 M
Net Income Applicable To Common Shares95.5 M100.3 M
Interest Income1.8 M1.9 M
Net Interest Income1.8 MM
Change To Netincome14.8 M15.5 M
Net Income Per Share 0.67  0.71 
Income Quality 2.01  2.11 
Net Income Per E B T 0.76  1.11 

Catalyst Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Catalyst Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Catalyst Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Catalyst Pharmaceuticals' important profitability drivers and their relationship over time.

Use Catalyst Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalyst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Catalyst Pharmaceuticals Pair Trading

Catalyst Pharmaceuticals Pair Trading Analysis

The ability to find closely correlated positions to Catalyst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalyst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalyst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalyst Pharmaceuticals to buy it.
The correlation of Catalyst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalyst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalyst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalyst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Catalyst Pharmaceuticals position

In addition to having Catalyst Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Investor Favorites Thematic Idea Now

Investor Favorites
Investor Favorites Theme
Macroaxis most traded equities with largest long positions over the last 2 years. The Investor Favorites theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investor Favorites Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.